Conferences, company updates and press releases
2-3 December 2026; London, UK Dr. Alan Barge, CEO, will present our work titled "Identifying Novel Immunotherapy Targets Using Human-Relevant Tumour Models"
20 August 2026 Preclinical data for lead asset Anti-4CB1, a first-in-class HVEM-blocking antibody
18 August 2026 Dr. Barge brings over 25 years in oncology drug development and joins as 4C Biomed prepares to enter the clinic
21 July 2026 U.S. Patent No. 12,686,722, "Anti-HVEM Antibodies and Use Thereof" extending protection for the lead program in the USA
22 June 2026; San Diego, CA, USA Dr. Alan Barge presented our work titled "A novel, BTLA/CD160 dual-targeting anti-HVEM immunotherapeutic for cancer" at the Innovator's Pitch Challenge
4 December 2025; London, UK Dr. Eyal Greenberg, CEO, presented our work titled "Anti-4CB1 - A first-in-class HVEM-Blocking antibody targeting Solid Tumors" at the Innovator's Pitch Challenge, Therapeutics session
10 January 2025 Chinese Patent No. CN 114026124 B, "Anti-HVEM Antibodies and Use Thereof" extending protection for the lead program in China
18 April 2024; London, UK Dr. Eyal Greenberg, CEO, presented our work titled "Finding new targets to fight cancer; Anti-4CB1 - A first-in-class HVEM-Blocking antibody targeting Solid Tumors" at the Clinical Stage pitch session
11-13 May 2021 Dr. Eyal Greenberg, CEO, presented our work on Anti-4CB1, a first-in-class HVEM-blocking antibody
16 September 2020 Dr. Eyal Greenberg, CEO, presented our work titled "Applying systematic discovery platform towards the discovery of high-quality targets"
This website uses cookies and similar technologies such as web beacons and pixels (collectively: “cookies”). These cookies are required in order to load our website or to enable you to use certain services that our website offers. We cannot provide you with access to the website or services without these cookies, and therefore these cookies cannot be disabled. For more details, you can read our privacy policy here.